Laurus Labs has received an approval from the US Food & Drug Administration (USFDA) under PEPFAR (President’s Emergency Plan for AIDS Relief) for two ANDAs (Abbreviated New Drug Application) TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg) and TLE 600 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/600mg) tablets.
Laurus Labs is one of the few players in the ARV segment to receive an approval for TLE 400 tablets. TLE 400 is one of the most preferred regimens in the ARV first line treatment. The company already received WHO Pre-Qualification for TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg). These approvals enable Laurus Labs to launch both the products in several LMIC markets.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1816.00 |
| Dr. Reddys Lab | 1276.00 |
| Cipla | 1325.30 |
| Zydus Lifesciences | 908.05 |
| Lupin | 2339.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: